We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+19.45%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$334M
AUM Growth
+$46.3M
Cap. Flow
+$21.1M
Cap. Flow %
6.32%
Top 10 Hldgs %
61.83%
Holding
47
New
7
Increased
16
Reduced
9
Closed
6
Avg Time Held
6.5 quarters
Top 10 Avg Time Held
3.8 quarters
Top 20 Avg Time Held
5 quarters

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$7.26M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.28M
3
TBPH icon
Theravance Biopharma
TBPH
+$4.85M
4
KZR icon
Kezar Life Sciences
KZR
+$3.62M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$3.57M

Top Sells

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.37M
2
WHWK icon
Whitehawk Therapeutics
WHWK
+$3.23M
3
MRSN icon
Mersana Therapeutics
MRSN
+$2.7M
4
FENC icon
Fennec Pharmaceuticals
FENC
+$2.61M
5
PRQR icon
ProQR Therapeutics
PRQR
+$2.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HROW icon
1
Harrow
HROW
$1.06B
$79.9M 23.92%
3,775,000
– –
2018 Q3
18 quarters
OCUL icon
2
Ocular Therapeutix
OCUL
$1.61B
$32.2M 9.64%
6,105,900
+30,900
+0.5% +$147K
2019 Q1
16 quarters
TELA icon
3
TELA Bio
TELA
$49.7M
$22.1M 6.61%
2,072,813
– –
2019 Q4
13 quarters
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$6.05B
$13.1M 3.93%
735,000
– –
2022 Q2
3 quarters
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$12.6M 3.78%
785,794
+53,794
+7% +$996K
2021 Q1
8 quarters
KPTI icon
6
Karyopharm Therapeutics
KPTI
$9.44M
$10.9M 3.27%
187,387
+106,931
+133% +$5.28M
2022 Q4
1 quarter
KROS icon
7
Keros Therapeutics
KROS
$222M
$10.2M 3.04%
238,000
– –
2021 Q1
8 quarters
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$9M 2.7%
238,225
+8,725
+4% +$286K
2020 Q3
10 quarters
ETON icon
9
Eton Pharmaceutcials
ETON
$1.55B
$8.41M 2.52%
2,185,000
+15,000
+0.7% +$54.7K
2018 Q4
17 quarters
TARA icon
10
Protara Therapeutics
TARA
$158M
$8.08M 2.42%
2,692,594
– –
2019 Q3
14 quarters
BHVN icon
11
Biohaven
BHVN
$1.7B
$7.38M 2.21%
540,000
– –
2022 Q4
1 quarter
CYTK icon
12
Cytokinetics
CYTK
$8.65B
$7.3M 2.19%
207,500
-42,500
-17% -$1.73M
2020 Q2
11 quarters
KALV icon
13
DELISTED
KalVista Pharmaceuticals
KALV
$7.26M 2.17%
923,200
– –
2022 Q4
1 quarter
PCVX icon
14
Vaxcyte
PCVX
$10.6B
$6.63M 1.99%
177,000
– –
2020 Q3
10 quarters
LRMR icon
15
Larimar Therapeutics
LRMR
$225M
$6.35M 1.9%
1,401,000
-159,000
-10% -$831K
2021 Q2
7 quarters
TBPH icon
16
DELISTED
Theravance Biopharma
TBPH
$5.93M 1.78%
546,304
+458,704
+524% +$4.85M
2022 Q4
1 quarter
ARQT icon
17
Arcutis Biotherapeutics
ARQT
$3.33B
$5.52M 1.65%
+502,000
New +$7.26M
2023 Q1
0 quarters
FDMT icon
18
4D Molecular Therapeutics
FDMT
$692M
$5.4M 1.62%
314,000
-16,000
-5% -$311K
2021 Q4
5 quarters
JNCE
19
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.33M 1.6%
+2,880,000
New +$3.57M
2023 Q1
0 quarters
MRNS icon
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.28M 1.58%
765,000
-61,200
-7% -$384K
2022 Q4
1 quarter
XOMA icon
21
DELISTED
Xoma
XOMA
$5.13M 1.54%
243,000
– –
2017 Q1
24 quarters
EWTX icon
22
Edgewise Therapeutics
EWTX
$3.99B
$5M 1.5%
750,000
+138,600
+23% +$1.28M
2022 Q1
4 quarters
MOR icon
23
DELISTED
MorphoSys AG American Depositary Shares
MOR
$4.73M 1.42%
1,194,000
+297,400
+33% +$1.31M
2022 Q3
2 quarters
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.33B
$4.71M 1.41%
343,000
+204,200
+147% +$3.4M
2022 Q3
2 quarters
URGN icon
25
UroGen Pharma
URGN
$1.85B
$4.67M 1.4%
505,000
+16,344
+3% +$150K
2022 Q2
3 quarters
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2023 Portfolio in Review

As of Q1 2023, Opaleye Management held 47 positions worth $334M, up 16% from $288M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $21.1M of net new capital in Q1 2023, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Arcutis Biotherapeutics: 502,000 shares worth $5.52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ProQR Therapeutics, an estimated $2.47M trimmed.

  • Opaleye Management's largest Q1 2023 buy was Arcutis Biotherapeutics: 502,000 shares worth $5.52M.
  • Opaleye Management added most to Karyopharm Therapeutics in Q1 2023, an estimated $5.28M increase.
  • Opaleye Management's biggest Q1 2023 reduction was ProQR Therapeutics, cutting an estimated $2.47M.
  • Opaleye Management fully exited Zentalis Pharmaceuticals in Q1 2023, selling an estimated $3.37M.
  • Opaleye Management's ten largest holdings make up 62% of its $334M portfolio in Q1 2023.
  • Opaleye Management opened 7 new positions and closed 6 in Q1 2023.
  • Opaleye Management's portfolio value rose 16% quarter-over-quarter to $334M.

Based on Opaleye Management's 13F filing for Q1 2023, filed 15 May 2023.